Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores.
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study with a 12 week, 2-arm treatment period. Participants will attend a Screening visit within 3 weeks before randomization to confirm eligibility. Approximately 200 participants will be randomized using a 1:1 ratio to receive either BNC210 900 mg twice daily (b.i.d.) or matched placebo. Participants will then complete 12 weeks of treatment with their allocated study intervention. Participants will return to their study site at 2-weekly intervals to complete study assessments. Participants are then requested to attend a Follow-up visit at Week 15 (i.e., 3 weeks after their last study intervention is administered).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BNC210 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BNC210 | Drug | BNC210 900 mg twice daily (b.i.d.) for 12 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline on the Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores After 12 Weeks | The CAPS-5 is a 30-item structured interview used to diagnose PTSD and assess PTSD symptoms over the past month. Information about the frequency and intensity of each item is combined into a severity rating, and the CAPS-5 total symptom severity score is calculated by adding the severity scores for the 20 PTSD symptoms in the DSM-5. Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms. | Baseline, 4 weeks, 8 weeks,12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion B Symptom Cluster Scores After 12 Weeks | Criterion B (Intrusive Thoughts) is a 5-item sub section of the CAPS-5 scale that assesses intrusion symptoms associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 20, with higher scores indicating greater severity of intrusion symptoms. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ATTUNE Study Clinical Trial Site | Bellflower | California | 90706 | United States | ||
| ATTUNE Study Clinical Trial Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39647171 | Result | Papapetropoulos S, Doolin E, O'Connor S, Paul D, Odontiadis M, Jaros M, Rolan P, Stein MB. BNC210, an alpha7 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder. NEJM Evid. 2025 Jan;4(1):EVIDoa2400380. doi: 10.1056/EVIDoa2400380. Epub 2024 Dec 8. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BNC210 900 mg | BNC210 900 mg twice daily (b.i.d.) for 12 weeks |
| FG001 | Placebo | Placebo twice daily (b.i.d.) for 12 weeks |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 17, 2022 | Dec 16, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo twice daily (b.i.d.) for 12 weeks |
|
| Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion C Symptom Cluster Scores After 12 Weeks | Criterion C (Avoidance) is a 2-item sub section of the CAPS-5 scale that assesses avoidance of stimuli associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 8, with higher scores indicating greater severity of avoidance symptoms. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion D Symptom Cluster Scores After 12 Weeks | Criterion D (Negative Alterations in Cognitions and Mood) is a 7-item sub section of the CAPS-5 scale that assesses negative alterations in cognitions and mood associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 28, with higher scores indicating greater severity of negative alterations in cognitions and mood symptoms. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion E Symptom Cluster Scores After 12 Weeks | Criterion E (Arousal and Reactivity) is a 6-item sub section of the CAPS-5 scale that assesses marked alterations in arousal and reactivity associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 24, with higher scores indicating greater severity of arousal and reactivity symptoms. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Montgomery Asberg Depression Rating Scale (MADRS) Scores After 12 Weeks | The MADRS is a 10-item clinician-rated questionnaire to measure the presence and severity of depressive episodes. Each item is rated on a scale of 0 to 6. The score from each item is combined into a total score ranging from 0 to 60, with higher scores indicating greater severity of depressive episodes. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Hamilton Anxiety Rating Scale (HAM-A) Scores After 12 Weeks | The HAM-A is an interview questionnaire that measures severity of anxiety symptoms based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior during the interview. Each parameter is rated on a scale of 0 (not present) to 4 (very severe). The score from each parameter is combined into a total score. Scores range from 0 to 56, with higher scores indicating greater severity of anxiety symptoms. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Clinician Global Impression - Severity (CGI-S) Scale Scores After 12 Weeks | The CGI-S is a rating scale designed to assess the overall severity of the participant's symptoms. Severity is rated on a scale from 1 (normal, not at all ill) to 7 (among the most extremely ill of participants), with a higher score indicating greater severity of symptoms. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Patient Global Impression - Severity (PGI-S) Scale Scores After 12 Weeks | Change from Baseline on patient-reported global functioning The PGI-S is a patient self-reported counterpart of the CGI-S designed to assess the patient's impression of their perceived severity of overall symptoms.Severity is rated on the PGI-S from 1 (normal) to 6 (very severe), with a higher score indicating greater severity of symptoms. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Insomnia Severity Index (ISI) Scores After 12 Weeks | The ISI is a brief self-report instrument measuring both nocturnal and diurnal symptoms of insomnia. The ISI comprises seven items, each scored from 0 to 4. The scores from each of the 7 questions are added up to get a total score of 0 to 28, with a higher score indicating a higher level of symptom severity. | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Change From Baseline on Sheehan Disability Scale (SDS) Scores After 12 Weeks | The SDS is a rating scale designed to measure impairment in three domains: work/school, social life, and family life/home responsibilities. Each item is rated on a scale of 0 (not at all) to 10 (extremely), for a total score of 0 to 30, with a higher score indicating a higher degree of impairment. | Baseline, 4 weeks, 8 weeks,12 weeks |
| Change From Baseline on PTSD Checklist for DSM-5 (PCL-5) Scores After 12 Weeks | The PCL-5 is a 20-item self-report assessment of the 20 DSM-5 symptoms of PTSD. Each symptom is rated on a scale from 0 (not at all) to 4 (extremely). Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms. | Baseline, 12 weeks |
| Beverly Hills |
| California |
| 90210 |
| United States |
| ATTUNE Study Clinical Trial Site | Colton | California | 92324 | United States |
| ATTUNE Study Clinical Trial Site | Oceanside | California | 92056 | United States |
| ATTUNE Study Clinical Trial Site | Orange | California | 92868 | United States |
| ATTUNE Study Clinical Trial Site | Temecula | California | 92591 | United States |
| ATTTUNE Study Clinical Trial Site | Jacksonville | Florida | 32256 | United States |
| ATTUNE Study Clinical Trial Site | Lauderhill | Florida | 33319 | United States |
| ATTUNE Study Clinical Trial Site | Miami Lakes | Florida | 33016 | United States |
| ATTUNE Study Clinical Trial Site | Orlando | Florida | 32801 | United States |
| ATTUNE Study Clinical Trial Site | Overland Park | Kansas | 66221 | United States |
| ATTUNE Study Clinical Trial Site | Prairie Village | Kansas | 66208 | United States |
| ATTUNE Study Clinical Trial Site | New Bedford | Massachusetts | 02740 | United States |
| ATTUNE Study Clinical Trial Site | Las Vegas | Nevada | 89102 | United States |
| ATTUNE Study Clinical Trial Site | Berlin | New Jersey | 08009 | United States |
| ATTUNE Study Clinical Trial Site | Cherry Hill | New Jersey | 08002 | United States |
| ATTUNE Study Clinical Trial Site | Cedarhurst | New York | 11516 | United States |
| ATTUNE Study Clinical Trial Site | Staten Island | New York | 10312 | United States |
| ATTUNE Study Clinical Trial Site | North Canton | Ohio | 44720 | United States |
| ATTUNE Study Clinical Trial Site | Oklahoma City | Oklahoma | 73106 | United States |
| ATTUNE Study Clinical Trial Site | West Chester | Pennsylvania | 19380 | United States |
| ATTUNE Study Clinical Trial Site | Memphis | Tennessee | 38119 | United States |
| ATTUNE Study Clinical Trial Site | Austin | Texas | 78737 | United States |
| ATTUNE Study Clinical Trial Site | Dallas | Texas | 75231 | United States |
| ATTUNE Study Clinical Trial Site | Draper | Utah | 84020 | United States |
| ATTUNE Study Clinical Trial Site | Barnsley | S75 3DL | United Kingdom |
| ATTUNE Study Clinical Trial Site | Blackpool | FY2 0JH | United Kingdom |
| ATTUNE Study Clinical Trial Site | Cannock | WS11 0BN | United Kingdom |
| ATTUNE Study Clinical Trial Site | Leeds | LS10 1DU | United Kingdom |
| ATTUNE Study Clinical Trial Site | Liverpool | L34 1BH | United Kingdom |
| ATTUNE Study Clinical Trial Site | Manchester | M13 9NQ | United Kingdom |
| ATTUNE Study Clinical Trial Site | Stockton-on-Tees | TS17 6EW | United Kingdom |
| Received Any Trial Drug |
|
| Modified Intent-To-Treat (mITT) | Includes all participants who received any trial drug and had at least one post-baseline Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) assessment (week 4, unless the participant completed a CAPS-5 assessment at an early termination visit between weeks 2 and 4). |
|
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BNC210 900 mg | BNC210 900 mg twice daily (b.i.d.) for 12 weeks |
| BG001 | Placebo | Placebo twice daily (b.i.d.) for 12 weeks |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| CAPS-5 Score | The Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) is a 30-item structured interview used to diagnose PTSD and assess PTSD symptoms over the past month. Information about the frequency and intensity of each item is combined into a severity rating, and the CAPS-5 total symptom severity score is calculated by adding the severity scores for the 20 PTSD symptoms in the DSM-5. Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms. | Mean | Standard Deviation | Total Symptom Severity Score |
| ||||||||||||||
| CGI-S score | The Clinician Global Impression - Severity (CGI-S) is a rating scale designed to assess the overall severity of the participant's symptoms. Severity is rated on a scale from 1 (normal, not at all ill) to 7 (among the most extremely ill of participants), with a higher score indicating greater severity of symptoms. | Mean | Standard Deviation | units on a scale |
| ||||||||||||||
| Time Since Index Trauma Event | Time since index trauma event occurring that caused PTSD | Mean | Standard Deviation | years |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline on the Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5) Total Symptom Severity Scores After 12 Weeks | The CAPS-5 is a 30-item structured interview used to diagnose PTSD and assess PTSD symptoms over the past month. Information about the frequency and intensity of each item is combined into a severity rating, and the CAPS-5 total symptom severity score is calculated by adding the severity scores for the 20 PTSD symptoms in the DSM-5. Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks,12 weeks |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion B Symptom Cluster Scores After 12 Weeks | Criterion B (Intrusive Thoughts) is a 5-item sub section of the CAPS-5 scale that assesses intrusion symptoms associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 20, with higher scores indicating greater severity of intrusion symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion C Symptom Cluster Scores After 12 Weeks | Criterion C (Avoidance) is a 2-item sub section of the CAPS-5 scale that assesses avoidance of stimuli associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 8, with higher scores indicating greater severity of avoidance symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion D Symptom Cluster Scores After 12 Weeks | Criterion D (Negative Alterations in Cognitions and Mood) is a 7-item sub section of the CAPS-5 scale that assesses negative alterations in cognitions and mood associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 28, with higher scores indicating greater severity of negative alterations in cognitions and mood symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Criterion E Symptom Cluster Scores After 12 Weeks | Criterion E (Arousal and Reactivity) is a 6-item sub section of the CAPS-5 scale that assesses marked alterations in arousal and reactivity associated with the traumatic event(s) of PTSD, with each item rated on a scale from 0 (not present) to 4 (extreme / incapacitating). Scores range from 0 to 24, with higher scores indicating greater severity of arousal and reactivity symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Montgomery Asberg Depression Rating Scale (MADRS) Scores After 12 Weeks | The MADRS is a 10-item clinician-rated questionnaire to measure the presence and severity of depressive episodes. Each item is rated on a scale of 0 to 6. The score from each item is combined into a total score ranging from 0 to 60, with higher scores indicating greater severity of depressive episodes. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Hamilton Anxiety Rating Scale (HAM-A) Scores After 12 Weeks | The HAM-A is an interview questionnaire that measures severity of anxiety symptoms based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior during the interview. Each parameter is rated on a scale of 0 (not present) to 4 (very severe). The score from each parameter is combined into a total score. Scores range from 0 to 56, with higher scores indicating greater severity of anxiety symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Clinician Global Impression - Severity (CGI-S) Scale Scores After 12 Weeks | The CGI-S is a rating scale designed to assess the overall severity of the participant's symptoms. Severity is rated on a scale from 1 (normal, not at all ill) to 7 (among the most extremely ill of participants), with a higher score indicating greater severity of symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Patient Global Impression - Severity (PGI-S) Scale Scores After 12 Weeks | Change from Baseline on patient-reported global functioning The PGI-S is a patient self-reported counterpart of the CGI-S designed to assess the patient's impression of their perceived severity of overall symptoms.Severity is rated on the PGI-S from 1 (normal) to 6 (very severe), with a higher score indicating greater severity of symptoms. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Insomnia Severity Index (ISI) Scores After 12 Weeks | The ISI is a brief self-report instrument measuring both nocturnal and diurnal symptoms of insomnia. The ISI comprises seven items, each scored from 0 to 4. The scores from each of the 7 questions are added up to get a total score of 0 to 28, with a higher score indicating a higher level of symptom severity. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks, 12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on Sheehan Disability Scale (SDS) Scores After 12 Weeks | The SDS is a rating scale designed to measure impairment in three domains: work/school, social life, and family life/home responsibilities. Each item is rated on a scale of 0 (not at all) to 10 (extremely), for a total score of 0 to 30, with a higher score indicating a higher degree of impairment. | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 4 weeks, 8 weeks,12 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline on PTSD Checklist for DSM-5 (PCL-5) Scores After 12 Weeks | The PCL-5 is a 20-item self-report assessment of the 20 DSM-5 symptoms of PTSD. Each symptom is rated on a scale from 0 (not at all) to 4 (extremely). Scores range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms. | The number of participants analyzed in the placebo group differs from the total number of participants in the placebo arm in the mITT population due to a missed assessment for 1 participant at Baseline | Posted | Least Squares Mean | Standard Error | score on a scale | Baseline, 12 weeks |
|
|
15 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | BNC210 900 mg | BNC210 900 mg twice daily (b.i.d.) for 12 weeks | 0 | 105 | 0 | 105 | 36 | 105 |
| EG001 | Placebo | Placebo twice daily (b.i.d.) for 12 weeks | 0 | 104 | 2 | 104 | 25 | 104 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cholelithiasis | Hepatobiliary disorders | MedDRA (24.0) | Systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA (24.0) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | MedDRA (24.0) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (24.0) | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA (24.0) | Systematic Assessment |
| |
| Eleveted Liver Enzymes | Investigations | MedDRA (24.0) | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| SVP Clinical Development | Bionomics Limited | +61 8 8150 7400 | BNC210clinicalstudies@bionomics.com.au |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 2, 2023 | Dec 16, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D013313 | Stress Disorders, Post-Traumatic |
| ID | Term |
|---|---|
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| United Kingdom |
|
|
|
|
|
|
|
|
|
|
|
|